// App-Quantinova.ai

TCT-583 : Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation a Novolimus-Eluting Coronary Stent System with Bioabsorbable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: 12- Month Clinical and 6-Month Angiographic and IVUS Results: the EXCELLA BD Study

Researchers

Presenter

  • Alexandre Abizaid

Principal Investigators

  • Roberto Botelho

  • Joachim Schofer

  • Stefan Verheye

  • Ricardo Costa

  • Luiz Fernando Tanajura

  • Katsuhisa Waseda

  • Lynn Morrison

  • Sara Toyloy

  • Peter Fitzgerald

Medical Centers

  • Cardiovascular, Stanford, California

  • Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, Antwerp, Belgium

  • Medical Care Center Prof Mathey, Prof Schofer, Hamburg University Cardiovascular Center, Hamburg, Germany

  • Stanford Univeresity Medical Center, Stanford, CA

  • Visiting Professor Columbia University, Sao Paulo, Brazil

  • ICU, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

  • Triangulo Heart Institute, Uberlandia, Brazil

  • Dante Pazzanese, Sao Paulo, Brazil

Locations

  • United States

  • Germany

  • Brazil

  • Belgium

Companies

  • Elixir medical corpo

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Restenosis

Biomarkers

  • N/A

Drug/Treatment

  • ZoMaxx

  • Rapacan

  • Choline bitartrate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved